![Jack Lawler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 4 000 $ op 31-05-2026
Mr. Jack Lawler is a Chief Development Officer at Chemomab Therapeutics Ltd. Mr. Lawler was previously employed as a VP-Clinical Operations & Data Management by Goldfinch Bio, Inc. He received his undergraduate degree from Rosemont College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-03-2026 | 40.000 ( 0,01% ) | 4 000 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Corporate Officer/Principal | 15-04-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 3 |
|---|---|
Rosemont College
 Rosemont College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Health Technology |
Chemomab Therapeutics Ltd.
 Chemomab Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotech company | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
